Dresden

• A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease Recruiting
  2024-515732-68-00 1 2025-03-07 Huntington’s disease
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept Recruiting
  2024-516380-81-00 4 2025-02-28 Treatment of IgAN
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni … Recruiting
  2023-510292-65-00 5 2025-02-25 chronic graft-versus-host disease
• Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients … Recruiting
  2023-507754-33-00 4 2025-02-19 steroid-refractory chronic Graft-versus-Host-Disease
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors. Recruiting
  2024-516440-25-00 1 2025-02-06 KRAS G12D-mutant solid tumors.
• A phase II, multicenter, 1:1 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of bolus applicatio … Recruiting
  2024-511037-35-00 4 2025-01-31 Cyclosporine A is a well known medication and is used to prevent rejec
• A Multi-centered, Double-blind, Randomized, Placebo-controlled Study of TEV-56286 for the Treatment of Multiple System Atrophy Recruiting
  2023-505320-54-00 4 2025-01-30 Multiple System Atrophy
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• A study to evaluate the efficacy and safety of frexalimab, brivekimig or rilzabrutinib in participants aged 16 to 75 years with primary foca … Recruiting
  2024-511775-15-00 4 2025-01-17 Immune system diseases
• ZELA trial: Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developi … Recruiting
  2024-513420-41-00 10 2025-01-09 prematurity in neonates
• Partial or total removal of the pancreas and transplantation of the patient's own islet cells in patients with pancreatic cancer and a high … Recruiting
  2023-507773-17-00 4 2024-12-11 Patients with perampullary carcinoma and a high-risk profile to develo
• A Phase 2 study to Evaluate the Safety, Tolerability and Efficacy of Efgartigimod PH20 SC given by prefilled syringe in Kidney Transplant Re … Recruiting
  2023-508180-72-00 4 2024-12-11 Antibody-Mediated Rejection
• Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in … Recruiting
  2023-504925-38-00 4 2024-12-10 patients with hormone receptor (HR)-positive, HER2-negative locally ad
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subject … Recruiting
  2024-513860-25-00 9 2024-12-10 Ovarian Neoplasms
• This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting
  2023-504713-76-00 5 2024-12-03 Dermatitis atopic
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)
• ENhanced recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis after primary Hip Arthroplasty Recruiting
  2023-507490-18-00 5 2024-11-26 Patients undergoing elective unilateral primary hip arthroplasty, who
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease

Showing 313–336 of 943 trials